Insmed, Inc. insider trading
INSMfinancial statementsForm 4 filings on EDGAR560 transactions since Nov 1, 2024
From August 4, 2026 to November 1, 2026, 0 insiders at Insmed, Inc. bought $0 of stock in the open market, and 4 sold $39M. Officers and directors accounted for $0 of purchases and $39M of sales. The last reported transaction was an award by Koppikar Utpal on October 19, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 20, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $39MAug 4, 2026 – Nov 1, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Oct 30, 2026. Insider data through Nov 1, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
560 transactions from November 1, 2024 to November 1, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | Koppikar Utpal | Director | award | 6,139 | — | — | 6,139 | Oct 20, 2026 |
| Oct 19, 2026 | Hudson Paul | Director | award | 6,139 | — | — | 6,139 | Oct 20, 2026 |
| Sep 9, 2026 | Brennan David R | Director | open-market sale | 25,000 | $124.00 | $3M | 39,238 | Sep 11, 2026 |
| Aug 17, 2026 | Sharoky Melvin MD | Director | open-market saleindirect | 5,000 | $127.53 | $638K | 0 | Aug 19, 2026 |
| Aug 10, 2026 | Adsett Roger | Chief Operating Officer | option exercise | 82,280 | $13.67 | $1M | 181,024 | Aug 12, 2026 |
| Aug 10, 2026 | Adsett Roger | Chief Operating Officer | option exercise | 76,600 | $17.16 | $1M | 257,624 | Aug 12, 2026 |
| Aug 10, 2026 | Adsett Roger | Chief Operating Officer | option exercise | 80,970 | $30.46 | $2M | 338,594 | Aug 12, 2026 |
| Aug 10, 2026 | Adsett Roger | Chief Operating Officer | open-market sale | 239,850 | $133.27 | $32M | 98,744 | Aug 12, 2026 |
| Aug 6, 2026 | Flammer Martina M.D. | Chief Medical Officer | option exercise | 18,278 | $18.95 | $346K | 78,764 | Aug 7, 2026 |
| Aug 6, 2026 | Flammer Martina M.D. | Chief Medical Officer | option exercise | 8,895 | $25.83 | $230K | 87,659 | Aug 7, 2026 |
| Aug 6, 2026 | Flammer Martina M.D. | Chief Medical Officer | open-market sale10b5-1 | 8,895 | $127.00 | $1M | 78,764 | Aug 7, 2026 |
| Aug 6, 2026 | Flammer Martina M.D. | Chief Medical Officer | open-market sale10b5-1 | 18,278 | $129.40 | $2M | 60,486 | Aug 7, 2026 |
| Jul 23, 2026 | Lewis William | Chair and CEO, Director | option exercise | 6,260 | $30.46 | $191K | 265,318 | Jul 24, 2026 |
| Jul 23, 2026 | Lewis William | Chair and CEO, Director | option exercise | 4,440 | $17.16 | $76K | 269,758 | Jul 24, 2026 |
| Jul 23, 2026 | Lewis William | Chair and CEO, Director | open-market sale10b5-1 | 4,828 | $105.62 | $510K | 264,930 | Jul 24, 2026 |
| Jul 23, 2026 | Lewis William | Chair and CEO, Director | open-market sale10b5-1 | 5,872 | $106.43 | $625K | 259,058 | Jul 24, 2026 |
| Jul 9, 2026 | Lewis William | Chair and CEO, Director | option exercise | 6,259 | $30.46 | $191K | 265,317 | Jul 10, 2026 |
| Jul 9, 2026 | Lewis William | Chair and CEO, Director | option exercise | 4,440 | $17.16 | $76K | 269,757 | Jul 10, 2026 |
| Jul 9, 2026 | Lewis William | Chair and CEO, Director | open-market sale10b5-1 | 5,005 | $116.55 | $583K | 264,752 | Jul 10, 2026 |
| Jul 9, 2026 | Lewis William | Chair and CEO, Director | open-market sale10b5-1 | 2,335 | $117.62 | $275K | 262,417 | Jul 10, 2026 |
| Jul 9, 2026 | Lewis William | Chair and CEO, Director | open-market sale10b5-1 | 3,359 | $118.52 | $398K | 259,058 | Jul 10, 2026 |
| Jul 6, 2026 | Flammer Martina M.D. | Chief Medical Officer | option exercise | 7,945 | $29.13 | $231K | 68,431 | Jul 8, 2026 |
| Jul 6, 2026 | Flammer Martina M.D. | Chief Medical Officer | option exercise | 4,357 | $19.74 | $86K | 72,788 | Jul 8, 2026 |
| Jul 6, 2026 | Flammer Martina M.D. | Chief Medical Officer | open-market sale10b5-1 | 4,854 | $109.02 | $529K | 67,934 | Jul 8, 2026 |
| Jul 6, 2026 | Flammer Martina M.D. | Chief Medical Officer | open-market sale10b5-1 | 7,448 | $110.60 | $824K | 60,486 | Jul 8, 2026 |
| Jun 25, 2026 | Lewis William | Chair and CEO, Director | option exercise | 12,518 | $30.46 | $381K | 271,435 | Jun 26, 2026 |
| Jun 25, 2026 | Lewis William | Chair and CEO, Director | option exercise | 8,880 | $17.16 | $152K | 280,315 | Jun 26, 2026 |
| Jun 25, 2026 | Lewis William | Chair and CEO, Director | open-market sale10b5-1 | 12,091 | $102.34 | $1M | 268,224 | Jun 26, 2026 |
| Jun 25, 2026 | Lewis William | Chair and CEO, Director | open-market sale10b5-1 | 1,836 | $103.10 | $189K | 266,388 | Jun 26, 2026 |
| Jun 25, 2026 | Lewis William | Chair and CEO, Director | open-market sale10b5-1 | 3,723 | $104.28 | $388K | 262,665 | Jun 26, 2026 |
| Jun 25, 2026 | Lewis William | Chair and CEO, Director | open-market sale10b5-1 | 2,456 | $105.27 | $259K | 260,209 | Jun 26, 2026 |
| Jun 25, 2026 | Lewis William | Chair and CEO, Director | open-market sale10b5-1 | 1,292 | $106.27 | $137K | 258,917 | Jun 26, 2026 |
| Jun 23, 2026 | Butera Samuele | SVP, GM, Global Respiratory | award | 7,342 | — | — | 7,342 | Jun 24, 2026 |
| Jun 22, 2026 | Smith Michael Alexander | Chief Legal Officer | open-market sale10b5-1 | 1,806 | $95.82 | $173K | 37,648 | Jun 24, 2026 |
| Jun 8, 2026 | Lewis William | Chair and CEO, Director | open-market sale10b5-1 | 6,515 | $94.03 | $613K | 258,917 | Jun 10, 2026 |
| Jun 5, 2026 | Flammer Martina M.D. | Chief Medical Officer | open-market sale10b5-1 | 1,858 | $103.78 | $193K | 60,486 | Jun 5, 2026 |
| Jun 3, 2026 | Adsett Roger | Chief Operating Officer | open-market sale | 2,370 | $102.27 | $242K | 98,603 | Jun 5, 2026 |
| Jun 3, 2026 | Bonstein Sara | Chief Financial Officer | open-market sale | 2,404 | $102.27 | $246K | 69,082 | Jun 5, 2026 |
| Jun 3, 2026 | Smith Michael Alexander | Chief Legal Officer | open-market sale | 2,159 | $102.27 | $221K | 39,454 | Jun 5, 2026 |
| Jun 3, 2026 | Lewis William | Chair and CEO, Director | open-market sale | 7,605 | $102.27 | $778K | 265,432 | Jun 5, 2026 |
| Jun 3, 2026 | Flammer Martina M.D. | Chief Medical Officer | open-market sale10b5-1 | 2,566 | $102.27 | $262K | 62,344 | Jun 5, 2026 |
| May 22, 2026 | Smith Michael Alexander | Chief Legal Officer | open-market sale10b5-1 | 6,149 | $108.47 | $667K | 41,613 | May 22, 2026 |
| May 18, 2026 | Lewis William | Chair and CEO, Director | option exercise | 6,259 | $30.46 | $191K | 294,161 | May 20, 2026 |
| May 18, 2026 | Lewis William | Chair and CEO, Director | option exercise | 4,440 | $17.16 | $76K | 298,601 | May 20, 2026 |
| May 18, 2026 | Lewis William | Chair and CEO, Director | open-market sale10b5-1 | 5,753 | $105.32 | $606K | 292,848 | May 20, 2026 |
| May 18, 2026 | Lewis William | Chair and CEO, Director | open-market sale10b5-1 | 11,836 | $106.39 | $1M | 281,012 | May 20, 2026 |
| May 18, 2026 | Lewis William | Chair and CEO, Director | open-market sale10b5-1 | 7,975 | $106.97 | $853K | 273,037 | May 20, 2026 |
| May 14, 2026 | Flammer Martina M.D. | Chief Medical Officer | open-market sale10b5-1 | 10,479 | $117.54 | $1M | 64,910 | May 15, 2026 |
| May 13, 2026 | Bonstein Sara | Chief Financial Officer | open-market sale | 8,272 | $116.18 | $961K | 71,486 | May 15, 2026 |
| May 13, 2026 | Schafer Carol | Director | award | 3,305 | — | — | 66,622 | May 15, 2026 |
Who the insiders are
Everyone who reported a transaction since November 1, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Adsett Roger | Chief Operating Officer | Aug 10, 2026 | option exercise | 181,024 | — | $48M (10) | 3 of 10 |
| Lewis William | Chair and CEO, Director | Jul 23, 2026 | option exercise | 265,318 | — | $33M (74) | 68 of 74 |
| Flammer Martina M.D. | Chief Medical Officer | Aug 6, 2026 | option exercise | 78,764 | — | $23M (40) | 40 of 40 |
| Schaeffer Orlov S Nicole | Chief People Strategy Officer | Jan 2, 2026 | award | 41,754 | — | $21M (9) | 5 of 9 |
| Lee Leo | Director | May 13, 2026 | award | 57,971 | — | $15M (5) | 0 of 5 |
| Smith Michael Alexander | Chief Legal Officer | Jun 22, 2026 | open-market sale | 37,648 | — | $14M (20) | 14 of 20 |
| Sharoky Melvin MD | Director | Aug 17, 2026 | open-market sale | 246,081 | — | $5M (2) | 0 of 2 |
| Brennan David R | Director | Sep 9, 2026 | open-market sale | 39,238 | — | $3M (1) | 0 of 1 |
| Anderson Elizabeth M | Director | May 13, 2026 | award | 62,034 | — | $3M (2) | 0 of 2 |
| Bonstein Sara | Chief Financial Officer | Jun 3, 2026 | open-market sale | 69,082 | — | $2M (6) | 0 of 6 |
| Wise John Drayton | Chief Commercial Officer | Feb 7, 2025 | open-market sale | 133,015 | — | — | — |
| Mcgirr David W J | Director | Feb 9, 2026 | gift | 44,323 | — | — | — |
| Desjardins Clarissa | Director | May 13, 2026 | award | 70,312 | — | — | — |
| Schafer Carol | Director | May 13, 2026 | award | 66,622 | — | — | — |
| Koppikar Utpal | Director | Oct 19, 2026 | award | 6,139 | — | — | — |
| Hudson Paul | Director | Oct 19, 2026 | award | 6,139 | — | — | — |
| Butera Samuele | SVP, GM, Global Respiratory | Jun 23, 2026 | award | 7,342 | — | — | — |
Questions
Are Insmed, Inc. insiders buying or selling?
Over the twelve months to November 1, 2026, 10 insiders at Insmed, Inc. sold $167M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $167M. Only open-market purchases and sales are counted.
Who sold the most Insmed, Inc. stock in the last year?
Adsett Roger (Chief Operating Officer) sold $48M in 10 open-market sales over the twelve months to November 1, 2026.
Do Insmed, Inc. executives sell under 10b5-1 plans?
130 of the 169 open-market sales in the last twelve months (77%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Insmed, Inc.
- Insmed, Inc. financial statements
- 2 tracked funds holding INSM
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.